(Q36080695)

English

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

Riccardi A

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ucci G

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Luoni R

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Brugnatelli S

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Mora O

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Spanedda R

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

De Paoli A

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Barbarano L

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Di Stasi M

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Alberio F

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 December 1994

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

70

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1203-1210

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

Treatment of adult acute non-lymphoblastic leukemia: a computer-aided analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

Management of refractory myeloma: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

Changing clinical presentation of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

2 October 2017

Peptichemio, vincristine, prednisone induction treatment in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

11 July 2018

Peptichemio induction therapy in myelomatosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

23 September 2018

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

23 September 2018

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033710

23 September 2018

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokinetic changes in two cases of plasma leukemia treated with a multipeptide derivative of m-[di(2-chloroethyl)amino]-L-phenylalanine (Peptichemio)

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptichemio in multiple myeloma. (Preliminary results)

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proliferative activity, response to therapy and survival in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete remission in plasma cell leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of the MRC myelomatosis trials for patients entered since 1980

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of p170 protein in multiple myeloma: a clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unmaintained remissions in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1994.474

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36080695&oldid=2198170718"